Jane Street Group LLC Has $90,000 Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Jane Street Group LLC cut its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 46.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,397 shares of the company’s stock after selling 30,000 shares during the quarter. Jane Street Group LLC owned 0.07% of Kodiak Sciences worth $90,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new stake in shares of Kodiak Sciences during the 3rd quarter worth about $751,000. FMR LLC increased its holdings in Kodiak Sciences by 26.4% in the third quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after buying an additional 41,987 shares during the last quarter. State Street Corp raised its position in Kodiak Sciences by 1.8% during the third quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after acquiring an additional 14,711 shares in the last quarter. Sei Investments Co. raised its position in Kodiak Sciences by 27.1% during the second quarter. Sei Investments Co. now owns 143,841 shares of the company’s stock valued at $338,000 after acquiring an additional 30,683 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Kodiak Sciences in the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on KOD shares. HC Wainwright restated a “neutral” rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Friday, November 15th. Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, December 9th. Finally, Barclays boosted their target price on Kodiak Sciences from $3.00 to $4.00 and gave the stock an “underweight” rating in a report on Friday, November 15th.

Kodiak Sciences Trading Down 2.7 %

Kodiak Sciences stock opened at $7.60 on Wednesday. Kodiak Sciences Inc. has a 1 year low of $2.18 and a 1 year high of $11.60. The company’s 50-day moving average is $7.76 and its two-hundred day moving average is $4.56. The company has a market cap of $399.94 million, a PE ratio of -2.08 and a beta of 2.11.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.